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IntercalationAbstract In the ﬁeld of antitumor DNA-intercalating agents, 9-anilinoacridines play an important
role due to their antiproliferative properties. Several cancer chemotherapeutics such as amascrine
and nitracrine have been developed as anticancer agents. In the present study, several 2-methyl-9
substituted (AS 0–8) acridines were synthesized by nucleophilic substitution of 2-methyl-9-chloro-
acridine (AS) with aromatic amines. The structures of novel compounds were determined using
spectroscopic methods. Three compounds were evaluated for antiproliferative activity against A-
549 (Human, small cell lung carcinoma) and MCF-7 (Human, breast cancer) cell lines using the
MTT assay. Compound AS-2 showed higher in vitro cytotoxic activity against A-549 and MCF-7
cancer cell lines with CTC50 187.5 and 212.5 lg/ml respectively. The cancer cell cytotoxicity of acri-
dines against A-549 cell line was found to be more active than MCF-7 cell line.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Cancer is a popular generic term for malignant neoplasms.
Malignant tumor is the most serious threat to human health in
the world. The word cancer comes fromLatin for crab probably
because of the way a cancer adheres to any part that it seizesupon in an obstinatemanner like the crab. It is a popular generic
term whereas the actual medical term for cancer is neoplasia
which comes from Greek meaning new formation (Parkin
et al., 2005). Malignant neoplasm refers to the fact that the
new growth has virulent or adverse properties that may be dis-
played in the body. Through expression of these properties, it
can cause destruction of major organs, and in some cases, life
threatening disturbances in body function (Alberg et al., 2005;
Cohen et al., 2005). It is verywell documented that an anticancer
drug for a complete treatment of cancer is yet to be discovered.
The current failure of cancer treatment could be attributed to
the development of multidrug resistance (MDR) (Dimanche-
Boitrel et al., 1993). This phenomenon is of considerable
economic importance and often has grave consequences for
health. It also serves as a major challenge to the pharmaceutical
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effective drugs become limited in their usefulness. The repeated
use of chemotherapeutics leads the organism to become ineffec-
tive due to the onset of resistance or tolerance by the target cells
or organism. The above setbacks have posed a major problem
for the effective treatment of cancer as well as infectious
diseases.
Acridine derivatives constitute a class of compounds that
are used for commercial means for more than a century. Its
derivatives are one of the more studied chemotherapeutic com-
pounds, widely used as antimalarial, antiviral, antibacterial,
antitumor, antiprotozoal, and antitubercular agents (Gamage
et al., 1994; Valdes 2011; Goodwell et al., 2006; Wainwright
2001; Guddneppanavar et al., 2006; Giorgia et al., 2007; Aly
and Abadi, 2004) and their antitumor activity with DNA-
intercalative properties have been studied (Michael et al.,
2004; Bacherikov et al., 2005). Ehrlich and Benda in 1912 pro-
posed the use of acridine dyes as antibacterial agents and in
1917 it was clinically used as antibacterial. Acridine has been
used as anti-infective agent for many years and now a vast
majority of patients are dedicated to its use as antitumor agent.
Quinacrine hydrochloride represents a good example of this
statement, as it was launched in 1932 for the treatment of ma-
laria and is now in clinical trial for the treatment of Creutz-
feldt–Jakob disease, prostate cancer and advanced renal cell
carcinoma (Belmont and Dorange, 2008). Amascrine also
known as m-AMSA, obtained by Denny’s group was the ﬁrst
synthetic drug that was approved for clinical use in 1976 for
the treatment of leukemia. Nitracrine dihydrochloride hydrate
also known as Ledakrin, developed by Ledochowski’s group,
is another oncolytic drug that was launched in the 1980s and
approved for the clinical use.
Amascrine is the best known compound of 9-aminoacridine
series (Su et al., 1995; Kohn et al., 1994). It was one of the ﬁrst
DNA intercalating agents to be considered as topoisomerase II
inhibitor. It forms a ternary complex in which acridine is inter-
calated into DNA and the aniline side chain interacts with the
enzyme. The stabilization of topoisomerase II-DNA cleavage
complex by amascrine inhibits enzyme mediated DNA relega-
tion (Denny, 2002). Among various derivatives of amascrine,
asulacrine (CI-921) displayed interesting properties and went
through phase I/II clinical trials. Both amascrine and asulacrine
undergo reversible oxidation forming chemically reactive qui-
none-diimine which excreted by conjugation with thiols such
as glutathione (Demeunynck et al., 2001). The new analogs
were prepared to prevent their oxidation in which the substitu-
ents on aniline ring are in meta position to each other and be-
came unable to form the quinone-diimine intermediate. In
2003 they prepared m-hydroxymethyl substituted derivatives
having AHMA as lead compound (Chang et al., 2003). The
CH2OH function of AHMA was replaced by methyl group at
ortho, meta and para-positions to NH2 group to form AOT,
AMT and APT compounds with the introduction of dimethyla-
minoethylcarboxamido and methyl group at C4 and C5 of acri-
dine ring. These compounds show better in vivo cytotoxicity
than AHMA. Further compounds AOA, AMA and APA with
the methoxy group in place of methyl group at ortho, meta,
para-positions to NH2 have been prepared. Among them
AOA exhibited a higher cytotoxicity than AMA and APA.
Overall order of toxicity was AMAs > AMTs > AOAs >
AOTs > APTs > APAs (Denny et al., 1982; Su et al., 1995;
Belmont et al., 2007). A further AHMA-alkylcarbamatederivative that possesses a carbamate group has been prepared
with a signiﬁcant anticancer effect and lesser toxicity than
amascrine (Su et al., 1999). The signiﬁcant clinical use of several
of these compounds is limited by problems such as side effects,
drug resistance and poor bioavailability, which have encour-
aged further modiﬁcations to these compounds. Thus, with
the purpose to discover better antiproliferative agents, a new
series of 2-methylacridine derivatives were prepared.2. Experimental
All the chemicals used for the synthetic work were purchased
from Central Drug House Pvt. Ltd. (CDH), New Delhi and
Hi-Media Laboratories Pvt. Ltd. Mumbai. Melting points were
determined by using Veego microprocessor based programma-
ble melting point apparatus in open capillaries and are uncor-
rected. The progress of reaction was monitored by TLC on
silica gel G plates using Chloroform:Methanol (8:2) solvent sys-
tem. Infra red (IR) spectra were recorded in KBr pellets on Shi-
madzu IR-Afﬁnity Fourier Transformation spectrophotometer
(mmax in cm1). 1H-NMR spectra were recorded on BRUKER
AVANCE II 400 NMR spectrometer using CDCl3 and DMSO-
d6 as solvents and TMS as internal standard (chemical shift val-
ues expressed in d ppm), Elemental analyses were carried out on
a Perkin–Elmer 2400 CHN elemental analyzer.
2.1. Synthesis
2.1.1. Synthesis of 2-(p-tolylamino) benzoic acid
A mixture of o-chlorobenzoic acid (0.04 mol), p-toluidine
(0.08 mol), sodium acetate (4.1 g), copper powder (0.2 g), cop-
per oxide (0.1 g) and DMF (25 ml) was reﬂuxed for 2 h at 160–
170 C. The mixture was then cooled and poured into water
and acidiﬁed with concentrated hydrochloric acid. The precip-
itates so obtained were ﬁltered and washed with hot water.
Recrystallized product (light yellow crystals) was recovered
from ethanol using charcoal. Yield: 74% (4.6 g), m.p.: 184 C.
2.1.2. Synthesis of 2-methyl-9-chloroacridine
A mixture of 2-(p-tolylamino) benzoic acid (0.022 mol) and
freshly distilled phosphorous oxychloride (0.176 mol) was
slowly heated for about 15 min at 85–90 C on a water bath
and when the boiling subsided it was heated on a heating man-
tle for 2 h at 140–150 C. The excess of oxychloride was re-
moved by distillation. The residue after cooling was poured
into a well-stirred mixture of cooled concentrated ammonia
and chloroform (1:1). The mixture was stirred for 30 min.
When no more undissolved solid remained, the chloroform
layer was separated and extracts were dried over calcium chlo-
ride, ﬁltered and ﬁnally the solvent was evaporated. A greenish
powder was obtained as product.
2-Methyl-9-chloroacridine (AS)
Yield 86%; m.p. 146 C; IR t (cm1): 3026.31 (ArC-H),
2831.50 (C-H), 1600.92 and 1473.62 (ArC = C), 1340.53 (C-
N), 775.3 and 756.10 (=C-H), 563.21 (C-Cl); 1H-NMR
(CDCl3): d 2.49 (s, 3H, CH3), 7.49–7.54 (m, 2H, ArH), 7.66–
7.70 (m, 1H, ArH), 8.01 (s, 1H, ArH), 8.06–8.08 (d, 1H,
J= 8.88 Hz, ArH), 8.15–8.18 (d, 1H, J= 8.76 Hz, ArH),
8.26–8.28 (d, 1H, J= 8.64 Hz, ArH).
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The substituted aromatic amines (0.011 mol) were dissolved in
50 ml of methanol and reﬂuxed with 2-methyl-9-chloroacridine
AS (1.14 g, 0.005 mol) for different hrs at 50–60 C. TLC using
chloroform: methanol as solvent (8:2) was used for the conﬁrma-
tion of the completion of the reaction and visualized in an iodine
chamber. The reactionmixturewas cooled and poured into diethyl
ether. The hydrochloric salts were precipitated, ﬁltered and recrys-
tallized with ethanol/ether to give red, yellow or orange color.
2-Methyl-9-(phenylamino) acridine hydrochloride (AS-0)
Yield 88%; m.p. 278–279 C; IR t (cm1): 3566.64 (N–H),
3049.36 (ArC–H), 2831.60 (C–H), 1581.63 and 1517.98
(ArC‚C), 1338.60 (C–N), 775.38 and 750.31 (‚C–H); 1H-
NMR (DMSO-d6): d 2.40 (s, 3H, –CH3), 7.12–8.11 (m, 12H,
ArH), 11.2 (s, 1H, NH), 15.2 (s, 1H, HCl). Anal. Calcd for
C20H17ClN2: C, 74.88; H, 5.34; N, 8.73. Found: C, 74.50; H,
5.21; N, 8.67.
2-Methyl-9-[(40-methoxy)phenylamino]acridine hydrochloride
(AS-1)
Yield 82%; m.p. 270–271 C; IR t (cm1): 3500.30 (N–H),
3003.30 (ArC–H), 2831.3 (C–H), 1589.34 and 1508.33
(ArC‚C), 1340.53 (C–N), 1354.53 (C–O), 775.38 and 759.95
(‚C–H); 1H-NMR (DMSO-d6): d 2.41 (s, 3H, CH3), 3.87 (s,
3H, OCH3), 7.02–7.04 (t, 2H, J = 6.96 Hz, ArH), 7.27–7.32
(m, 3H, ArH), 7.73–7.75 (dd, 1H, J = 8.20 Hz, ArH), 7.82–
7.86 (t, 1H, J = 8.12 Hz, ArH), 8.05–8.07 (t, 1H, J = 4.76 Hz,
ArH), 8.11–8.15 (t, 3H, J = 9.52 Hz, ArH), 11.29 (br s, 1H, –
NH), 14.60 (s, 1H, HCl). Anal. Calcd for C21H19ClN2O: C,
71.89; H, 5.46; N, 7.98. Found: C, 71.64; H, 5.38; N, 7.80.
2-Methyl-9-[(3’-chloro)phenylamino]acridine hydrochloride
(AS-2)
Yield 82%; m.p. 238 C; IR t (cm1): 3566.38 (N–H), 3064.89
(ArC–H), 2829.57 (C–H), 1595.13 and 1512.19 (ArC‚C),
1365.50 (C–N), 775.38 and 754.17 (‚C–H), 553.57 (C–Cl);
1H-NMR (DMSO-d6): d 2.43 (s, 3H, CH3), 6.48–6.55 (m, 2H,
ArH), 6.94–6.98 (t, 1H, J = 1.96 Hz, ArH), 7.31–7.48 (m,
1H, ArH), 7.75–7.77 (d, 1H, J = 8.72 Hz, ArH), 7.86–7.89 (t,
1H, J = 7.48 Hz, ArH), 8.16–8.25 (m, 5H, ArH), 11.2 (s, 1H,
–NH), 15.1 (s, 1H, HCl). Anal. Calcd for C20H16Cl2N2: C,
67.62; H, 4.54; N, 7.89. Found: C, 67.38; H, 4.47; N, 7.69.
2-Methyl-9-[(4’-chloro)phenylamino]acridine hydrochloride
(AS-3)
Yield 71%; m.p. 275–276 C; IR t (cm1): 3523.95 (N–H),
3101.54 (ArC–H), 2829.57 (C–H), 1578.13 and 1548.84
(ArC‚C), 1278.81 (C–N), 775.38 and 750.31 (‚C–H),
549.71 (C–Cl); 1H-NMR (DMSO-d6): d 2.5 (s, 3H, CH3),
7.41–7.47 (m, 1H, ArH), 7.56–7.67 (m, 4H, ArH), 7.84–7.86
(d, 1H, J = 8.92 Hz, ArH), 7.93–7.97 (t, 1H, J = 7.40 Hz,
ArH), 8.14–8.25 (m, 4H, ArH), 11.36 (s, 1H, NH), 15.05 (s,
1H, HCl). Anal. Calcd for C20H16Cl2N2: C, 67.62; H, 4.54;
N, 7.89. Found: C, 67.36; H, 4.50; N, 7.72.
2-Methyl-9-[(4’-methyl)phenylamino]acridine hydrochloride
(AS-4)
Yield 88%; m.p. 279–280 C; IR t (cm1): 3523.95 (N–H),
3101.54 (ArC–H), 2738.92 (C–H), 1583.58 and 1508.33(ArC‚C), 1236.37 (C–N), 762.32 and 758.02 (‚C–H); 1H-
NMR (DMSO-d6): d 2.42 (s, 3H, CH3), 2.44 (s, 3H, CH3),
7.23–7.25 (d, 2H, J = 8.24 Hz, ArH), 7.29–7.33 (t, 3H,
J = 8.16 Hz, ArH), 7.76–7.79 (dd, 1H, J = 8.72 Hz, ArH),
7.85–7.89 (t, 1H, J = 7.44 Hz, ArH), 7.98–8.04 (t, 2H,
J = 8.72 Hz, ArH), 8.06–8.09 (t, 1H, J = 4.68 Hz, ArH),
8.12–8.14 (d, 1H, J = 9.08 Hz, ArH), 11.23 (s, 1H, –NH),
14.23 (s, 1H, HCl). Anal. Calcd for C21H19ClN2: C, 75.33;
H, 5.72; N, 8.37. Found: C, 75.28; H, 5.60; N, 8.24.
2-Methyl-9-[(3’-triﬂouromethyl)phenylamino]acridine
hydrochloride (AS-5)
Yield 79%; m.p. 274–275 C; IR t (cm1): 3423.95 (N–H),
3101.54 (ArC–H), 2830.31 (C–H), 1595.13 and 1508.08
(ArC‚C), 1338.60 (C–F), 1242.00 (C-N), 775.38 and 756.10
(‚C–H); 1H-NMR (DMSO-d6): d 2.54 (s, 3H, CH3), 7.35–7.41
(m, 3H, ArH), 7.46–7.48 (d, 2H, J = 8.72 Hz, ArH), 7.81–7.83
(t, 1H, J = 7.84 Hz, ArH), 7.90–7.94 (t, 1H, J = 7.68 Hz,
ArH), 8.09–8.16 (m, 3H, ArH), 8.21 (s, 1H, ArH), 11.31 (s, 1H,
–NH), 14.80 (s, 1H, HCl). Anal. Calcd for C21H16ClF3N2: C,
64.87; H, 4.15; N, 7.20. Found: C, 64.68; H, 4.05; N, 7.16.
2-Methyl-9-[(4’-triﬂouromethyl)phenylamino]acridine
hydrochloride (AS-6)
Yield 85%; m.p. 240–241 C, IR t (cm1): 3315.63 (N–H),
3161.33 (ArC–H), 2829.57 (C–H), 1583.56 and 1510.26
(ArC‚C), 1356.60 (C–F), 1276.88 (C-N), 775.38 and 754.17
(‚C–H); 1H-NMR (DMSO-d6): d 2.54 (s, 3H, CH3), 7.43–
7.50 (m, 3H, ArH), 7.69–7.71 (d, 2H, J = 8.44 Hz, ArH),
7.84–7.87 (dd, 1H, J = 8.74 Hz, ArH), 7.94–7.98 (t, 1H,
J = 7.36 Hz, ArH), 8.19–8.23 (m, 4H, ArH), 11.47 (s, 1H, -
NH), 15.23 (s, 1H, HCl). Anal. Calcd for C21H16ClF3N2: C,
64.87; H, 4.15; N, 7.20. Found: C, 64.70; H, 4.05; N, 7.10.
2-Methyl-9-[(4’-carboxy)phenylamino]acridine hydrochloride
(AS-7)
Yield 80%; m.p. 225 C (dec.); IR t (cm1): 3523.95 (N–H),
2951.09 (COOH), 3101.54 (ArC–H), 2829.57 (C–H), 1714.65
(C‚O), 1550.77 and 1508.33 (ArC‚C), 1255.66 (C–N),
775.38 and 754.17 (‚C–H); 1H-NMR (DMSO-d6): d 2.57 (s,
3H, CH3), 6.58–6.60 (d, 2H, J = 8.60 Hz, ArH), 7.18 (s, 1H,
ArH), 7.62 (s, 2H, ArH), 7.68–7.70 (d, 1H, J = 8.60 Hz,
ArH), 7.80–7.82 (t, 1H, J = 7.56 Hz, ArH), 7.87–7.93 (m,
1H, ArH), 8.03–8.05 (d, 1H, J = 8.56 Hz, ArH), 8.16–8.21
(m, 2H, ArH), 11.26 (s, 1H, –NH), 15.03 (br s, 1H, HCl). Anal.
Calcd for C21H17ClN2O2: C, 69.14; H, 4.70; N, 7.68. Found: C,
69.05; H, 4.64; N, 7.58.2-Methyl-9-[(2’-carboxy)phenylamino]acridine hydrochloride
(AS-8)
Yield 78%; m.p. 220 C (dec.); IR t (cm1): 3523.95 (N–H),
2951.09 (COOH), 3101.54 (ArC–H), 2831.50 (C–H), 1716.65
(C‚O), 1585.85 and 1541.12 (ArC‚C), 1236.37 (C–N),
773.24 and 752.24 (‚C–H); 1H-NMR (DMSO-d6): d 2.58 (s,
3H, CH3), 6.53–6.57 (t, 1H, J = 7.96 Hz, ArH), 6.71–6.73
(d, 1H, J = 8.28 Hz, ArH), 7.16–7.23 (m, 2H, ArH), 7.38–
7.52 (m, 2H, ArH), 7.76–7.83 (m, 2H, ArH), 7.91–7.98 (m,
1H, ArH), 8.11–8.18 (m, 1H, ArH), 8.32–8.39 (t, 1H,
J = 8.04 Hz, ArH), 11.37 (s, 1H, –NH), 11.60 (br, 1H,
–COOH), 15.57 (br s, 1H, HCl). Anal. Calcd for
Table 1 Physical data of the synthesized compounds.
Product code Structure M.P. (C) Time (hrs) Color
AS-0
N
CH3
HN
.HCl
278–279 8 Yellowish green
AS-1
N
CH3
HN
.HCl
OCH3
270–271 8 Dark yellow
AS-2
N
CH3
HN
.HCl
Cl 238 8 Greenish yellow
AS-3
N
CH3
HN
.HCl
Cl
275–276 5 Yellow
AS-4
N
CH3
HN
.HCl
CH3
279–280 8 Yellow
AS-5
N
CH3
HN
.HCl
CF3
274–275 6 Yellow
AS-6
N
CH3
HN
.HCl
CF3
240–241 5 Yellowish green
AS-7
N
CH3
HN
.HCl
COOH
225 (dec.) 7 Orange
AS-8
N
CH3
HN
.HCl
HOOC 220 (dec.) 9 Dark orange
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Scheme 1 a Sodium acetate, Cu Powder, CuO and DMF heating at 160–170 C for 2 h. b Cyclization by freshly distilled POCl3.
c Methanol, heating at 50–60 C with aromatic amine for different hrs.
S960 R. Kumar et al.C21H17ClN2O2: C, 69.14; H, 4.70; N, 7.68. Found: C, 69.08; H,
4.65; N, 7.60.
2.2. Cytotoxicity evaluation
2.2.1. Regents and chemicals
3-(4,5-Dimethyl thiazol-2-yl)-5-diphenyl tetrazolium bromide
(MTT), Fetal Bovine serum (FBS), Phosphate Buffered Saline
(PBS), Dulbecco’s Modiﬁed Eagle’s Medium (DMEM) and
Trypsin were obtained from Sigma Aldrich Co, St Louis,
USA, EDTA, Glucose and antibiotics from Hi-Media Labora-
tories Ltd., Mumbai, Dimethyl Sulfoxide (DMSO) and Propa-
nol from E. Merck Ltd., Mumbai, India.Table 2 In vitro antitumor activity of acridine derivatives.
Cell line Compound Concentration in lg/ml*
1000 500 250
A-549 AS-1 74.07 ± 0.04 57.29 ± 0.06 49.2
AS-2 81.04 ± 0.03 72.33 ± 0.04 67.9
AS-5 78.64 ± 0.03 61.65 ± 0.05 49.2
MCF-7 AS-1 72.76 ± 0.04 63.83 ± 0.05 51.4
AS-2 83.87 ± 0.02 76.90 ± 0.03 55.5
AS-5 73.85 ± 0.04 59.91 ± 0.06 44.4
Concentration in lg/ml
10 5 2.5
A-549 Taxol 78.95 ± 0.15 66.50 ± 0.08 58.7
MCF-7 Taxol 71.25 ± 0.14 63.45 ± 0.06 49.1
* Results are expressed as mean percent of MTT absorbance (ratio of a
represent means of three independent experiments ± SEM of n= 2, p<2.2.2. Cell lines and culture medium
A-549 (Human, small cell lung carcinoma) and MCF-7 (Hu-
man, Breast cancer) cell cultures were procured from the Na-
tional Centre for Cell Sciences (NCCS), Pune, India. Stock
cells were cultured in DMEM supplemented with 10% inacti-
vated Fetal Bovine Serum (FBS), penicillin (100 IU/ml), strep-
tomycin (100 lg/ml) and amphotericin B (5 lg/ml) in a
humidiﬁed atmosphere of 5% CO2 at 37 C until conﬂuent.
The cells were dissociated with TPVG solution (0.2% trypsin,
0.02% EDTA, 0.05% glucose in PBS). The stock cultures were
grown in 25 cm2 culture ﬂasks and all experiments were carried
out in 96 microtitre plates (Tarsons India Pvt. Ltd., Kolkata,
India).CTC50 in lg/ml
125 62.5
3 ± 0.07 14.16 ± 0.13 0.15 ± 0.17 300
7 ± 0.05 32.89 ± 0.10 16.35 ± 0.12 187.5
3 ± 0.07 17.86 ± 0.13 9.80 ± 0.13 262.5
1 ± 0.07 14.16 ± 0.13 0.00 ± 0.16 237.5
5 ± 0.06 37.25 ± 0.09 10.25 ± 0.13 212.5
4 ± 0.08 13.50 ± 0.13 4.13 ± 0.14 337.5
1.25 0.625
5 ± 0.09 42.76 ± 0.04 19.67 ± 0.03 1.65
5 ± 0.05 33.45 ± 0.04 19.50 ± 0.05 2.75
bsorbance in test compound treated and control cells). Data points
0.01.
Figure 2 Cytotoxic assay of test samples by MTT againstMCF-
7 cell line after 72 h of drug treatment.
Figure 1 Cytotoxic assay of test samples by MTT against A-549
cell line after 72 h of drug treatment.
Synthesis, characterization and antitumor activity of 2-methyl-9-substituted acridines S9612.2.3. Preparation of test solutions
For cytotoxicity studies, each weighed test drug was separately
dissolved in distilled DMSO and the volume was made up with
DMEM supplemented with 2% inactivated FBS to obtain a
stock solution of 1 mg/ml concentration and sterilized by ﬁl-
tration. Serial two fold dilutions were prepared from this for
carrying out cytotoxic studies.
2.2.4. Cell viability by MTT assay
Cell viability following exposure to synthetic compounds was
estimated by using the MTT reduction assay (Mosmann
1983; Francis and Rita, 1986; Antonini et al., 2006). The
monolayer cell culture was trypsinized and the cell count was
adjusted to 1.0 · 105 cells/ml using DMEM medium contain-
ing 10% FBS. To each well of the 96 microtitre plate, 0.1 ml
of the diluted cell suspension (approximately 10,000 cells)
was added. After 24 h, when a partial monolayer was formed,
the supernatant was ﬂicked off, the monolayer was washed
once with medium and 100 ll of different test concentrations
of test drugs were added onto the partial monolayer in micro-
titre plates. The plates were then incubated at 37 C for 3 days
in 5% CO2 atmosphere, and microscopic examination was car-
ried out and observations were noted every 24 h interval. After
72 h, the drug solutions in the wells were discarded and 50 ll of
MTT in PBS was added to each well. The plates were gently
shaken and incubated for 3 h at 37 C in 5% CO2 atmosphere.
The supernatant was removed, 100 ll of propanol was added
and the plates were gently shaken to solubilize the formed for-
mazan. The absorbance was measured using a microplate read-
er at a wavelength of 540 nm. The percentage growth
inhibition was calculated using the following formula andthe concentration of the test drug needed to inhibit cell growth
by 50% (CTC50) values was generated from the dose–response
curves for each cell line (Cookson et al., 2005; Yim et al.,
2005). Each experiment was done in triplicate and results are
expressed as means ± SEM for each determination. The fol-
lowing formula was used for the calculation of the percentage
of cell viability (CV): CV (%) = (A of the individual test
group/A of the control group) · 100.3. Results and discussion
3.1. Chemistry
2-Methyl-9-substituted acridines (AS 0–8) were synthesized
and given in Table 1. p-toluidine was a starting intermediate
for the synthesis of 9-substituted acridines. Sodium acetate
was used as a base where as Cu metal (catalyst) and CuO
are used as co-catalysts to give 2-(p-tolylamino) benzoic acid.
The product was treated with POCl3 which gives 2-methyl-9-
chloroacridine, AS (Boyer et al., 1999). AS was dissolved in
methanol using different aromatic amines and reﬂuxed for
different hrs. at 50–60 C to give corresponding 9-substituted
derivatives of 2-methyl acridines as shown in Scheme 1 (Ha-
gan et al., 1997). 1H-NMR and IR data reveal the structure
of molecules of newly synthesized acridine derivatives. In
IR, the structure was conﬁrmed by functional group identiﬁ-
cation. Secondary amine gave its peak at 3570–3400 cm1.
C‚O peak of the carboxylic group appeared at 1716–
1714 cm1 along with a broad peak of –COOH at 3000–
2800 cm1. C–F peaks appeared at about 1350–1300 cm1.
Whereas C–Cl peaks appeared at about 750–700 cm1. C–O
peak of ether is at 1345 cm1. In 1H-NMR, the structure
was conﬁrmed by the no. of proton, splitting of signals,
and value of chemical shift in ppm. Peaks appearing at about
11.2–11.4 ppm represent NH proton, COOH peak appeared
at about 11.6 ppm whereas –OCH3 and –CH3 gave their
peaks at 2–5 ppm.
3.2. Cytotoxicity
The majority of drugs used for the treatment of cancer today
are cytotoxic drugs that work by interfering in some way with
the operation of cell’s DNA. 9-anilinoacridine based drugs
show good anticancer activity e.g. amascrine, nitracrine,
DACA etc. Inspired from the anticancer activities of amas-
crine, we design new 9-anilinoacridines for anticancer evalua-
tion based upon molecular modiﬁcation. Antitumor activity
was done on two cancer cell lines (A-549 and MCF-7) by
MTT assay. Three compounds (AS-1, AS-2 and AS-5) were se-
lected on the basis of the results of previous work for an eval-
uation of antiproliferative activity on both cell lines (Kumar
et al., 2013). Compound AS-2 showed good activity against
A-549 and MCF-7 cancer cell lines with CTC50 187.5 and
212.5 lg/ml respectively as shown in Table 2 and Figs. 1 and
2. All the evaluated compounds showed more activity against
A-549 cell line as compared to MCF-7 cell line. Other com-
pounds AS-1 and AS-5 showed a signiﬁcant activity against
(A-549) cancer cell lines with CTC50 300 and 262.5 lg/ml. Also
AS-1 and AS-5 showed a signiﬁcant activity against (MCF-7)
cancer cell lines with CTC50 237.5 and 337.5 lg/ml
respectively.
S962 R. Kumar et al.4. Conclusion
New acridine derivatives were prepared and evaluated for their
antiproliferative activity. Various structural modiﬁcations
were done on acridine ring as well as on aromatic ring attached
to 9-position of acridine ring. A series of derivatives was pre-
pared by substituting various electron withdrawing as well as
electron releasing groups on the aromatic ring attached to 9-
position of acridine ring. The new acridine derivatives are
found to possess signiﬁcant antiproliferative activity in vitro.
An electron withdrawing group on m-position of aromatic
amine was found to be more active than electron releasing
group. Also substitution of Cl group on m-position of 9-posi-
tion of acridine ring was found to be more active than CF3
group on the same position. Structural modiﬁcations may lead
to synthesize more acridine derivatives and can be evaluated
for their anticancer, antimalarial, anti-inﬂammatory activities
in vitro as well as in vivo.Declaration of interest
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